Showing results (141-150 of 175) with videos related to
Sort By:
Pageof 18
NPJ Precision Oncology|April 29, 2021
Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survivalVladimir Lazar, Shai Magidi, Nicolas Girard, et al.Lung Cancer (Amsterdam, Netherlands)|February 20, 2025
Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutationsAdel Shahnam, Alexander Davis, Lauren Julia Brown, et al.The New England Journal of Medicine|October 23, 2023
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLCCaicun Zhou, Benjamin Solomon, Herbert H Loong, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2016
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)Chris Karlovich, Jonathan W Goldman, Jong-Mu Sun, et al.Archives of Pathology & Laboratory Medicine|January 23, 2018
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular PathologyNeal I Lindeman, Philip T Cagle, Dara L Aisner, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 4, 2018
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular PathologyNeal I Lindeman, Philip T Cagle, Dara L Aisner, et al.The Journal of Molecular Diagnostics : JMD|February 6, 2018
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular PathologyNeal I Lindeman, Philip T Cagle, Dara L Aisner, et al.Therapeutic Advances in Medical Oncology|November 3, 2022
Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lungVladimir Lazar, Jacques Raynaud, Shai Magidi, et al.Future Oncology (London, England)|January 19, 2023
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS dataParneet Cheema, Byoung Chul Cho, Helano Freitas, et al.European Journal of Cancer (Oxford, England : 1990)|November 16, 2018
Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case seriesEmma L Mitchell, Peter Kar Han Lau, Chloe Khoo, et al.Pageof 18